Brief: China Regenerative Medicine International say Dai Yumin acquired 40 pct stake in All Favour
21/09/2017 12:37
Sept 21 (Reuters) - China Regenerative Medicine
International Ltd 8158.HK
* Voluntary announcement Dai Yumin acquired 40% All Favour
and became the sole beneficial owner of All Favour
* Deal at a consideration of approximately HK$340 million
Source text for Eikon: ID:nHKS2xKZQQ
Further company coverage: 8158.HK
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on China Regenerative Medicine International
See all newsBrief: China Regenerative Medicine International Expects FY Profit To Increase At Least 28%
Brief: China Regenerative Medicine International Says Yan Shibin Will Be Appointed As CFO
Brief: China Regenerative Medicine International Posts H1 Revenue Of HKD59.78 Mln
Brief: China Regenerative Medicine International Posts FY Loss Attributable HK$107.7 Mln
Brief: China Regenerative Medicine International Says Subscription Of Increased Registered Capital